[The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro]
- PMID: 7553760
[The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro]
Abstract
The resistance of bacterial strains to beta-lactam antibiotics (penicillins and cephalosporins) is due to transfer of genes coding the production of enzymes-beta-lactamases. These enzymes--penicillinases and cephalosporinases--can hydrolyse beta-lactam antibiotics. The using of beta-lactamase inhibitors in combination with some beta-lactam antibiotics is a suitable alternative in the present unfavourable situation in chemotherapy (increase of occurrence of gram-negative and gram-positive penicillin-cephalosporin-resistant bacterial strains). In this communication the authors present the review of efficiency of three, in clinical practice mostly used potentiated penicillins: Augmentin (amoxicillin + clavulanate), Unasyn (ampicillin + sulbactam) and Tazobac (piperacillin + tazobactam). Tazobactam seems to be the most promising beta-lactamase inhibitor which has, unlike clavulanate and sulbactam, its own antibiotic activity.
Similar articles
-
Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.Infection. 1991 Mar-Apr;19(2):106-9. doi: 10.1007/BF01645578. Infection. 1991. PMID: 1646771
-
Beta-lactamase inhibitors and Acinetobacter spp.J Antimicrob Chemother. 1990 Sep;26(3):449-51. doi: 10.1093/jac/26.3.449. J Antimicrob Chemother. 1990. PMID: 2172200 No abstract available.
-
Use of beta-lactam/beta-lactamase-inhibitor combinations as antimycobacterial agents.Microbios. 1993;76(309):251-61. Microbios. 1993. PMID: 8302203
-
Evolution of beta-lactamase inhibitors.Rev Infect Dis. 1991 Jul-Aug;13 Suppl 9:S727-32. doi: 10.1093/clinids/13.supplement_9.s727. Rev Infect Dis. 1991. PMID: 1656513 Review.
-
Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.Pharmacotherapy. 2000 Sep;20(9 Pt 2):213S-218S; discussion 224S-228S. doi: 10.1592/phco.20.14.213s.35045. Pharmacotherapy. 2000. PMID: 11001328 Review.